Interim results from the ongoing CANVAS (Canagliflozin Cardiovascular Assessment Study) clinical trial have found an increased risk of leg and foot amputations associated with the popular diabetes ...

The new indication is based on results of the CREDENCE trial, which found that canagliflozin reduced the risk of renal failure or death by 30% in those that had both type 2 diabetes and diabetic ...

Compared to placebo, canagliflozin reduced the risk of the composite primary endpoint (cardiovascular mortality, nonfatal MI, nonfatal stroke) by 14% (HR: 0.86; 95% CI: 0.75-0.97). Compared to placebo ...

The FDA will remove the Boxed Warning or Black Box Warning about increased leg and foot amputation risk from the packaging of type 2 diabetes drug canagliflozin. In explaining the change, the agency ...

Aging-related physiological decline and the accumulation of senescent or aging cells in bodily tissues can trigger a number of diseases. The removal of senescent cells, also known as "senolysis," can ...

A 76-year-old Filipina woman who had been taking rosuvastatin 40 mg per day without a problem for more than 5 years started developing pain and weakness in her thighs just days after starting on the ...

Rockville, MD - The US Food and Drug Administration (FDA) has approved a novel glucose-lowering agent, canagliflozin (Invokana, Janssen Pharmaceuticals) for the treatment of adults with type 2 ...

The Appraisal Committee considered evidence submitted by the manufacturer of canagliflozin and a review of this submission by the Evidence Review Group (ERG). Of the 6 randomised controlled trials in ...